Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DMAC NASDAQ:REPL NASDAQ:SPRB NASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMACDiaMedica Therapeutics$6.58-1.5%$6.46$3.19▼$7.49$340.11M1.4307,730 shs244,410 shsREPLReplimune Group$4.50-3.6%$5.03$2.68▼$17.00$351.25M0.423.87 million shs1.65 million shsSPRBSpruce Biosciences$157.82+0.8%$39.58$4.28▼$240.00$88.64M2.471.46 million shs136,155 shsUPXIUpexi$5.40-3.7%$6.61$1.90▼$22.57$318M-0.535.28 million shs3.49 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMACDiaMedica Therapeutics0.00%-0.90%-2.66%+57.42%+49.55%REPLReplimune Group0.00%-0.66%+30.06%-62.78%-60.56%SPRBSpruce Biosciences0.00%-9.09%+1,678.45%+1,812.97%+305.37%UPXIUpexi0.00%-14.96%-20.82%-27.81%+113.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMACDiaMedica Therapeutics$6.58-1.5%$6.46$3.19▼$7.49$340.11M1.4307,730 shs244,410 shsREPLReplimune Group$4.50-3.6%$5.03$2.68▼$17.00$351.25M0.423.87 million shs1.65 million shsSPRBSpruce Biosciences$157.82+0.8%$39.58$4.28▼$240.00$88.64M2.471.46 million shs136,155 shsUPXIUpexi$5.40-3.7%$6.61$1.90▼$22.57$318M-0.535.28 million shs3.49 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMACDiaMedica Therapeutics0.00%-0.90%-2.66%+57.42%+49.55%REPLReplimune Group0.00%-0.66%+30.06%-62.78%-60.56%SPRBSpruce Biosciences0.00%-9.09%+1,678.45%+1,812.97%+305.37%UPXIUpexi0.00%-14.96%-20.82%-27.81%+113.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDMACDiaMedica Therapeutics 2.50Moderate Buy$12.3387.44% UpsideREPLReplimune Group 1.91Reduce$6.5044.44% UpsideSPRBSpruce Biosciences 2.13Hold$131.25-16.84% DownsideUPXIUpexi 2.67Moderate Buy$15.50187.04% UpsideCurrent Analyst Ratings BreakdownLatest SPRB, DMAC, UPXI, and REPL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/16/2025SPRBSpruce BiosciencesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/14/2025REPLReplimune GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/14/2025SPRBSpruce BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/14/2025UPXIUpexiWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025DMACDiaMedica TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025DMACDiaMedica TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025REPLReplimune GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SPRBSpruce BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025UPXIUpexiWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/19/2025REPLReplimune GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underweight9/8/2025REPLReplimune GroupHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral(Data available from 10/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDMACDiaMedica TherapeuticsN/AN/AN/AN/A$0.95 per shareN/AREPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ASPRBSpruce Biosciences$1.30M68.28N/AN/A$52.47 per share3.01UPXIUpexi$15.81M20.11N/AN/A$1.01 per share5.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDMACDiaMedica Therapeutics-$24.44M-$0.69N/AN/AN/AN/A-78.99%-69.94%11/12/2025 (Estimated)REPLReplimune Group-$247.30M-$3.24N/AN/AN/AN/A-69.34%-52.81%11/11/2025 (Estimated)SPRBSpruce Biosciences-$53.04M-$86.21N/AN/AN/AN/A-177.45%-118.06%11/10/2025 (Estimated)UPXIUpexi-$13.68MN/A0.00∞N/A-86.54%-54.33%-31.28%N/ALatest SPRB, DMAC, UPXI, and REPL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025DMACDiaMedica Therapeutics-$0.15N/AN/AN/AN/AN/A11/11/2025Q2 2026REPLReplimune Group-$0.86N/AN/AN/A$0.50 millionN/A11/10/2025Q3 2025SPRBSpruce Biosciences-$15.56N/AN/AN/AN/AN/A8/12/2025Q2 2025DMACDiaMedica Therapeutics-$0.18-$0.18N/A-$0.18N/AN/A8/7/2025Q1 2026REPLReplimune Group-$0.83-$0.95-$0.12-$0.95$0.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ASPRBSpruce BiosciencesN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDMACDiaMedica TherapeuticsN/A7.557.55REPLReplimune Group0.216.946.94SPRBSpruce BiosciencesN/A2.602.60UPXIUpexiN/A1.741.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDMACDiaMedica Therapeutics10.12%REPLReplimune Group92.53%SPRBSpruce Biosciences91.71%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipDMACDiaMedica Therapeutics7.30%REPLReplimune Group5.20%SPRBSpruce Biosciences6.90%UPXIUpexi4.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDMACDiaMedica Therapeutics2051.69 million47.92 millionOptionableREPLReplimune Group21078.06 million74.00 millionOptionableSPRBSpruce Biosciences20562,000523,000OptionableUPXIUpexi13058.89 million56.29 millionOptionableSPRB, DMAC, UPXI, and REPL HeadlinesRecent News About These CompaniesWeiss Ratings Reiterates "Sell (D-)" Rating for Upexi (NASDAQ:UPXI)October 16 at 2:19 AM | americanbankingnews.comUpexi (NASDAQ:UPXI) Given Sell (D-) Rating at Weiss RatingsOctober 14, 2025 | marketbeat.comUpexi (UPXI) Valuation in Focus After Digital Asset Strategy Unveiled at Treasury ShowcaseOctober 13, 2025 | finance.yahoo.comCould Upexi's (UPXI) Digital Asset Treasury Push Reveal a New Core Strategy?October 11, 2025 | uk.finance.yahoo.comUpexi to Participate in Upcoming October Investor ConferencesOctober 6, 2025 | markets.businessinsider.comUpexi, Inc. to Participate in Multiple Investor Conferences in October 2025October 6, 2025 | quiverquant.comQUpexi, Inc. (NASDAQ:UPXI) Sees Large Growth in Short InterestOctober 4, 2025 | marketbeat.comUpexi adds SOL Big Brain to advisory committeeSeptember 30, 2025 | msn.comUpexi Welcomes SOL Big Brain to the Upexi Advisory CommitteeSeptember 30, 2025 | markets.businessinsider.comKathmere Capital Management LLC Makes New Investment in Upexi, Inc. $UPXISeptember 27, 2025 | marketbeat.comUpexi (UPXI) Expected to Announce Earnings on MondaySeptember 25, 2025 | marketbeat.comUpexi Inc: Upexi Reports Financial Results for Fiscal Year Ended June 30, 2025 and Provides Shareholders with Solana Treasury Update Since June 30, 2025September 25, 2025 | finanznachrichten.deUpexi, Inc. Reports Financial Results for Fiscal Year 2025 and Provides Update on Solana Treasury PerformanceSeptember 24, 2025 | quiverquant.comQUpexi Reports Financial Results for Fiscal Year Ended June 30, 2025 and Provides Shareholders with Solana Treasury Update Since June 30, 2025September 24, 2025 | globenewswire.comUpexi Stock Pops Pre-Market, Retail Chatter Surges On Growing Solana Treasury HoldingsSeptember 12, 2025 | msn.comUpexi's Stellar Gains: Solana Treasury Strategy Drives 129% Growth in SOL ValueSeptember 12, 2025 | econotimes.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Upexi, Inc. (NASDAQ: UPXI)September 11, 2025 | prnewswire.comUpexi Adjusted SOL per Share Increases 129% Since Treasury LaunchSeptember 11, 2025 | globenewswire.comSolana gains 5% as Forward Industries reveals $1.6 billion SOL treasury planSeptember 8, 2025 | fxstreet.comUpexi Engages in September 2025 Investor ConferencesSeptember 8, 2025 | tipranks.comUpexi to Participate in Upcoming September ConferencesSeptember 3, 2025 | manilatimes.netMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPRB, DMAC, UPXI, and REPL Company DescriptionsDiaMedica Therapeutics NASDAQ:DMAC$6.58 -0.10 (-1.50%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$6.71 +0.13 (+1.98%) As of 10/17/2025 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Replimune Group NASDAQ:REPL$4.50 -0.17 (-3.64%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$4.53 +0.03 (+0.67%) As of 10/17/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Spruce Biosciences NASDAQ:SPRB$157.82 +1.21 (+0.77%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$156.18 -1.64 (-1.04%) As of 10/17/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Upexi NASDAQ:UPXI$5.40 -0.21 (-3.74%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$5.48 +0.07 (+1.39%) As of 10/17/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
